Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 6 months–4 years, mRNA vaccines, with vial icons and dosages, May 2023*

For product- and vaccination history-specific dosages, administration intervals, and additional dose information, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

*ADDITIONAL HOMOLOGOUS BIVALENT mRNA DOSES ARE AUTHORIZED*
Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 5 years, mRNA vaccines, with vial icons and dosages, May 2023*

*For administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 6–11 years, mRNA vaccines, with vial icons and dosages, May 2023*

<table>
<thead>
<tr>
<th>COVID-19 vaccination status May 2023</th>
<th>Unvaccinated</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously received vaccine(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of doses indicated, by manufacturer</td>
<td>1 dose monovalent Moderna</td>
<td>3 doses monovalent Moderna and 1 dose bivalent mRNA</td>
</tr>
<tr>
<td></td>
<td>2 doses monovalent Moderna</td>
<td>3 doses monovalent Moderna</td>
</tr>
<tr>
<td></td>
<td>1 dose Moderna OR Pfizer-BioNTech Bivalent</td>
<td>1 dose monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td></td>
<td>3 doses Moderna Bivalent OR Pfizer-BioNTech Bivalent</td>
<td>2 doses monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td></td>
<td>2 doses Moderna Bivalent OR Pfizer-BioNTech Bivalent</td>
<td>1 dose monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td></td>
<td>1 dose Moderna Bivalent OR Pfizer-BioNTech Bivalent</td>
<td>1 dose Moderna Bivalent OR Pfizer-BioNTech</td>
</tr>
</tbody>
</table>

**ADDITIONAL BIVALENT mRNA DOSES ARE AUTHORIZED**

*For product-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 12 years and older, mRNA vaccines, with vial icons and dosages, May 2023*

<table>
<thead>
<tr>
<th>COVID-19 vaccination status May 2023</th>
<th>Unvaccinated</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously received vaccine(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of doses indicated, by manufacturer</td>
<td>3 doses monovalent Moderna OR 3 doses monovalent Pfizer-BioNTech</td>
<td>3 doses monovalent Moderna and 1 dose bivalent mRNA</td>
</tr>
<tr>
<td></td>
<td>2 doses monovalent Moderna</td>
<td>1 dose monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td></td>
<td>1 dose monovalent Moderna</td>
<td>2 doses monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td></td>
<td>3 doses monovalent Moderna</td>
<td>3 doses monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td></td>
<td>3 doses monovalent Pfizer-BioNTech</td>
<td>3 doses monovalent Pfizer-BioNTech</td>
</tr>
</tbody>
</table>

ADDITIONAL BIVALENT mRNA DOSES ARE AUTHORIZED*

*For administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 6 months–4 years**, mRNA vaccines, May 2023*

<table>
<thead>
<tr>
<th>COVID-19 vaccination status May 2023</th>
<th>Unvaccinated</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously received vaccine(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of doses indicated, by manufacturer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Unvaccinated
- 3 doses bivalent Moderna
- OR
- 3 doses bivalent Pfizer-BioNTech

### Vaccinated
- 1 dose monovalent Moderna
- 2 doses monovalent Moderna
- 3 doses monovalent Moderna
- 3 doses monovalent Moderna and 1 dose bivalent Moderna
- 1 dose monovalent Pfizer-BioNTech
- 2 doses monovalent Pfizer-BioNTech
- 3 doses monovalent Pfizer-BioNTech
- 2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech
- 1 dose bivalent Pfizer-BioNTech

---

ADDITIONAL HOMOLOGOUS BIVALENT mRNA DOSES ARE AUTHORIZED*

*For product- and vaccination history-specific dosages, administration intervals, and additional dose information, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

---

06/13/23
Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 5 years, mRNA vaccines, May 2023*

*For product- and vaccination-history-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

ADDITIONAL BIVALENT mRNA DOSES ARE AUTHORIZED*
Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 6 years and older**, mRNA vaccines, May 2023*

*For product-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech